Evaluating the 21-gene assay Recurrence Score® as a predictor of clinical response to 24 weeks of neoadjuvant exemestane in estrogen receptor-positive breast cancer

Fisher B, Brown A, Mamounas E et al (1997) Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from national surgical adjuvant breast and bowel project B-18. J Clin Oncol 15:2483–2493 Chia S, Swain SM, Byrd DR et al (2008) Locally advanced and inflammatory breast cancer. J Clin Oncol 26:786–790 Makris A, Powles TJ, Ashley SE et al (1998) A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer. Ann Oncol 9:1179–1184 Mauriac L, MacGrogan G, Avril A et al (1999) Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonie Bordeaux Groupe Sein (IBBGS). Ann Oncol 10:47–52 Mauri D, Pavlidis N, Ioannidis JP (2005) Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Can Inst 97:188–194 Semiglazov VF, Semiglazov VV, Dashyan GA et al (2007) Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer. Cancer 110:244–254 Ellis MJ, Suman VJ, Hoog J et al (2011) Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2–3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype–ACOSOG Z1031. J Clin Oncol 29:2342–2349 Goldhirsch A, Wood WC, Coates AS et al (2011) Strategies for subtypes––dealing with the diversity of breast cancer: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2011. Ann Oncol 22:1736–1747 Chang J, Powles TJ, Allred DC et al (2000) Prediction of clinical outcome from primary tamoxifen by expression of biologic markers in breast cancer patients. Clin Can Res 6:616–621 Miller WR, White S, Dixon JM et al (2006) Proliferation, steroid receptors and clinical/pathological response in breast cancer treated with letrozole. Br J Can 94:1051–1056 Toi M, Saji S, Masuda N et al (2011) Ki-67 index changes, pathological response and clinical benefits in primary breast cancer patients treated with 24 weeks of aromatase inhibition. Can Sci 102:858–865 Albain KS, Barlow WE, Shak S et al (2010) Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol 11:55–65 Mamounas EP, Tang G, Fisher B et al (2010) Association between the 21-gene recurrence score assay and risk of loco-regional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20. J Clin Oncol 28:1677–1683 Paik S, Shak S, Tang G et al (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. New Engl J Med 351:2817–2826 Tang G, Shak S, Paik S et al (2011) Comparison of the prognostic and predictive utilities of the 21-gene recurrence score assay and adjuvant! For women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20. Breast Can Res Treat 127:133–142 Paik S, Tang G, Shak S et al (2006) Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 24:3726–3734 National Comprehensive Cancer Network (NCCN) (2013) Clinical practice guidelines in oncology (NCCN®). Available at: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site Aebi S, Davidson T, Gruber G et al (2011) Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 22[Suppl 6: vi]:12–24 Harris L, Fritsche H, Mennel R et al (2007) American society of clinical oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25:5287–5312 Chang JC, Makris A, Gutierrez MC et al (2008) Gene expression patterns in formalin-fixed, paraffin-embedded core biopsies predict docetaxel chemosensitivity in breast cancer patients. Breast Can Res Treat 108:233–240 Gianni L, Zambetti M, Clark K et al (2005) Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol 23:7265–7277 Akashi-Tanaka S, Shimizu C, Ando M et al (2009) 21-Gene expression profile assay on core needle biopsies predicts responses to neoadjuvant endocrine therapy in breast cancer patients. Breast 18:171–174 Ellis MJ, Ma C (2007) Letrozole in the neoadjuvant setting: the P024 trial. Breast Can Res Treat 105[Suppl 1]:33–43 Kim C, Tang G, Pogue-Geile KL et al (2011) Estrogen receptor (ESR1) mRNA expression and benefit from tamoxifen in the treatment and prevention of estrogen receptor-positive breast cancer. J Clin Oncol 29:4160–4167 Sorlie T, Perou CM, Tibshirani R et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98:10869–10874 Dowsett M, Smith IE, Ebbs SR et al (2007) Prognostic value of Ki-67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Can Inst 99:167–170 Ellis MJ, Tao Y, Luo J et al (2008) Outcome prediction for estrogen receptor-positive breast cancer based on post neoadjuvant endocrine therapy tumor characteristics. J Natl Can Inst 100:1380–1388 Chia YH, Ellis MJ, Ma CX (2010) Neoadjuvant endocrine therapy in primary breast cancer: indications and use as a research tool. Br J Can 103:759–764